Endocrinology Search
Endocrinology Endocrinology
hyponatremia
HYPONATREMIA

Hyponatremia is serum sodium concentration <135 mEq/L due to failure of normal water excretion.

Most common causes are medication effects, fluid retention and syndrome of inappropriate antidiuretic hormone secretion (SIADH).

Volume status should be assessed to help determine the underlying cause.

Commonly, patients with hyponatremia are asymptomatic and it is only an incidental finding.

 

Hyponatremia Signs and Symptoms

Definition

  • Serum sodium concentration <135 mEq/L due to failure of normal water excretion
    • Severe hyponatremia is when there is <120 mEq/L serum sodium concentration
  • A disorder of water imbalance where there is a relative excess of body water compared to total body sodium and potassium content due to impaired renal water excretion
    • Usually associated with disturbance in the hormone that governs water balance which is vasopressin or also called antidiuretic hormone (ADH)

Etiology

  • Most common causes are medication effects, fluid retention and syndrome of inappropriate antidiuretic hormone secretion (SIADH)

Signs and Symptoms

  • Commonly, patients with hyponatremia are asymptomatic and it is only an incidental finding
  • Gradual decrease in sodium usually shows minimal symptoms whereas rapid decreases manifest severe symptoms
    • Severe symptoms are due to brain edema and increased intracranial pressure
  • Mild to moderate symptoms that are relatively nonspecific and occur most commonly in patients with severe chronic hyponatremia are the following:
    • Headache
    • Fatigue
    • Lethargy
    • Nausea and vomiting
    • Dizziness
    • Gait disturbances
    • Forgetfulness
    • Confusion
    • Muscle cramps
  • Severe symptoms include seizures, obtundation, coma and respiratory arrest
  • Acute intervention is needed if the following symptoms occur:
    • Polydipsia
    • Muscle cramps
    • Headaches
    • Falls
    • Confusion
    • Altered mental status
    • Obtundation
    • Coma
    • Status epilepticus

Epidemiology

  • Hyponatremia is the most common body fluid disorder and electrolyte imbalance encountered in clinical practice
    • Accounts to 15-30% of emergency admissions in hospital and associated with increased mortality, morbidity and length of hospital stay in patients presenting with a range of conditions
    • Increases risk of falls and osteoporosis and in severe cases it can be associated with mental state changes, including risk of coma and seizures

Pathophysiology

  • Osmolality (total concentration of solutes in water) of plasma plays a role in the pathophysiology of hyponatremia
  • Arginine vasopressin system and thirst strict regulation help maintain plasma osmolality
  • Increase in plasma osmolality leads to ADH secretion and water retention which decreases serum osmolality
  • Decrease in plasma osmolality decreases ADH that will result in diuresis of free water and a return to homeostasis
Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Endocrinology - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Low-carb diet ups energy expenditure during weight loss maintenance
Stephen Padilla, 28 Nov 2018
A low-carbohydrate diet increases energy expenditure during weight loss maintenance, consistent with the carbohydrate-insulin model, a study has shown. This metabolic effect may contribute to the success of obesity treatment, particularly among those with high insulin secretion.
Higher fasting glucose ups post-stroke mortality in Chinese diabetic patients
Natalia Reoutova, 5 days ago

A hospital-based observational cohort study finds an association between higher fasting blood glucose (FBG) levels and unfavourable outcomes, including death, among Chinese patients with diabetes mellitus (DM) following acute ischaemic stroke (AIS).
Liraglutide add-on to metformin sustained glycaemic control in T2D
Elaine Soliven, 6 days ago
Adding liraglutide to metformin led to a significantly longer duration of glycaemic control in patients with type 2 diabetes (T2D) compared with an oral antidiabetic drug (OAD), according to the LIRA-PRIME* study presented at ADA 2020.